GENE ONLINE|News &
Shanghai Startup Poised for $325M IPO on Nasdaq
With just 2 years into operation, Shanghai startup LianBio is set to go public on the Nasdaq. The firm release the term for the initial public offering (IPO) on Oct. 20, and it plans to raise $325 million to complete Phase 3 clinical trials of its lead drug candidates.
LianBio said it will launch 20 million shares with $15 to $17 per share and a 30-day option to purchase up to an additional 3 million shares.
LianBio said it will launch 20 million shares with $15 to $17 per share and a 30-day option to purchase up to an additional 3 million shares.
